» Articles » PMID: 30719238

Surface Binding Energy Landscapes Affect Phosphodiesterase Isoform-Specific Inhibitor Selectivity

Overview
Specialty Biotechnology
Date 2019 Feb 6
PMID 30719238
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

As human phosphodiesterase (PDE) proteins are attractive drug targets, a large number of selective PDE inhibitors have been developed. However, since the catalytic sites of PDE isoforms are conserved in sequence and structure, it remains unclear how these inhibitors discriminate PDE isoforms in a selective manner. Here we perform long-time scale molecular dynamics (MD) simulations to investigate the spontaneous association processes of a highly selective PDE2A inhibitor (BAY60-7550) with the catalytic pockets of six PDE isoforms. We found that the free-energy landscapes of PDE:BAY60-7550 interactions on the PDE surfaces are very different between various PDE isoforms; and the free-energy landscape of PDE2A forms a favorable low-energy pathway that not only drives BAY60-7550 toward the target binding site, but also guides BAY60-7750 to adopt its native binding conformation known from crystal structure. Thus, this study reveals that the inhibitor interactions with the PDE surface residues play an important role in its high selectivity for PDE2A, and thereby provides new fundamental insights into the PDE isoform-specific inhibitor selectivity.

Citing Articles

Long-Timescale Simulations Revealed Critical Non-Conserved Residues of Phosphodiesterases Affecting Selectivity of BAY60-7550.

Liu Q, Song M, Qiu Y, Leung E, Huang Q, Yao X Comput Struct Biotechnol J. 2022; 20:5136-5149.

PMID: 36187927 PMC: 9508422. DOI: 10.1016/j.csbj.2022.09.013.


Repurposing of thermally stable nucleic-acid aptamers for targeting tetrodotoxin (TTX).

Li Y, Song M, Gao R, Lu F, Liu J, Huang Q Comput Struct Biotechnol J. 2022; 20:2134-2142.

PMID: 35832627 PMC: 9092388. DOI: 10.1016/j.csbj.2022.04.033.


Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.

Zhu H, Du W, Song M, Liu Q, Herrmann A, Huang Q Comput Struct Biotechnol J. 2021; 19:467-476.

PMID: 33505639 PMC: 7809394. DOI: 10.1016/j.csbj.2020.12.035.


post-SELEX optimization of a G-quadruplex DNA aptamer binding to marine toxin gonyautoxin 1/4.

Song M, Li G, Zhang Q, Liu J, Huang Q Comput Struct Biotechnol J. 2020; 18:3425-3433.

PMID: 33294137 PMC: 7689369. DOI: 10.1016/j.csbj.2020.10.041.

References
1.
Tsai C, Kumar S, Ma B, Nussinov R . Folding funnels, binding funnels, and protein function. Protein Sci. 1999; 8(6):1181-90. PMC: 2144348. DOI: 10.1110/ps.8.6.1181. View

2.
Francis S, Corbin J . Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep. 2003; 4(6):457-65. DOI: 10.1007/s11934-003-0027-x. View

3.
Noble M, Endicott J, Johnson L . Protein kinase inhibitors: insights into drug design from structure. Science. 2004; 303(5665):1800-5. DOI: 10.1126/science.1095920. View

4.
Fleming Y, Frame M, Houslay M . PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci. 2004; 117(Pt 11):2377-88. DOI: 10.1242/jcs.01096. View

5.
Scapin G, Patel S, Chung C, Varnerin J, Edmondson S, Mastracchio A . Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry. 2004; 43(20):6091-100. DOI: 10.1021/bi049868i. View